SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc. today announced data from research on its therapeutic programs targeting hypoxia-inducible factor prolyl hydroxylase (HIF-PH) and connective tissue growth factor (CTGF) reported at the 40th annual meeting of the American Society of Nephrology (ASN) Renal Week November 2 – 5, 2007, in San Francisco, CA.
